Figure 4.

Zoledronic acid prevents chemotherapy-associated bone loss in premenopausal women. Shown are percentage changes in lumbar spine, total hip, and femoral neck bone mineral density (BMD) from baseline to 6 and 12 months. Patients were randomly assigned to chemotherapy plus zoledronic acid (4 mg every 3 months) or placebo for 12 months. ^ap < 0.001 (between group). P values were calculated using 2-sample t-tests for mean differences from baseline. Hershman DL, et al. J Clin Oncol. 2008; 26(29):4739–4745.⁴⁸ Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.